COVID-19 knowledge prevents biologics discontinuation : Data from an Italian multicenter survey during RED-ZONE declaration
© 2020 Wiley Periodicals LLC..
SARS-CoV-2 become pandemics and there is still a dearth of data about its the potentially among dermatological patients under biologics. We aimed to assess health literacy, disease knowledge, treatment dissatisfaction and biologics attitudes toward COVID-19. We performed a cross-sectional, questionnaire-based survey on 98/105 consecutive dermatological patients treated with biologics-51 suffering from plaque psoriasis, 22 from atopic dermatitis, and 25 from hidradenitis suppurativa. An ad hoc, validated questionnaire has 44 items investigating the following domains: knowledge of COVID-19 related to (a) epidemiology, (b) pathogenesis, (c) clinical symptoms, (d) preventive measures, and (e) attitudes. Patients data and questionnaires were collected. Despite only 8.1% thought that biologics may increase the risk of COVID-19, 18.4% and 21.4% of the patients were evaluating the possibility to discontinue or modify the dosage of the current biologic therapy, respectively. Globally, male patients (P = .001) with higher scholarity level (P = .005) displayed higher knowledge of COVID-19. Patients with lower DLQI (P = .006), longer disease duration (P = .051) and lower scholarity (P = .007) have thought to discontinue/modify autonomously their biologic therapy. At the multivariate logistic regression, only the knowledge of epidemiology and preventive measures resulted independent predictors of continuation vs discontinuation and modification vs no modification, respectively. Dermatologists should promote COVID-19 knowledge to prevent biologics disruption.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
---|---|
Enthalten in: |
Dermatologic therapy - 33(2020), 4 vom: 17. Juli, Seite e13508 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Bragazzi, Nicola Luigi [VerfasserIn] |
---|
Links: |
---|
Themen: |
Atopic dermatitis |
---|
Anmerkungen: |
Date Completed 25.11.2020 Date Revised 10.01.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1111/dth.13508 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM309983894 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM309983894 | ||
003 | DE-627 | ||
005 | 20231225135116.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1111/dth.13508 |2 doi | |
028 | 5 | 2 | |a pubmed24n1033.xml |
035 | |a (DE-627)NLM309983894 | ||
035 | |a (NLM)32415727 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Bragazzi, Nicola Luigi |e verfasserin |4 aut | |
245 | 1 | 0 | |a COVID-19 knowledge prevents biologics discontinuation |b Data from an Italian multicenter survey during RED-ZONE declaration |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 25.11.2020 | ||
500 | |a Date Revised 10.01.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2020 Wiley Periodicals LLC. | ||
520 | |a SARS-CoV-2 become pandemics and there is still a dearth of data about its the potentially among dermatological patients under biologics. We aimed to assess health literacy, disease knowledge, treatment dissatisfaction and biologics attitudes toward COVID-19. We performed a cross-sectional, questionnaire-based survey on 98/105 consecutive dermatological patients treated with biologics-51 suffering from plaque psoriasis, 22 from atopic dermatitis, and 25 from hidradenitis suppurativa. An ad hoc, validated questionnaire has 44 items investigating the following domains: knowledge of COVID-19 related to (a) epidemiology, (b) pathogenesis, (c) clinical symptoms, (d) preventive measures, and (e) attitudes. Patients data and questionnaires were collected. Despite only 8.1% thought that biologics may increase the risk of COVID-19, 18.4% and 21.4% of the patients were evaluating the possibility to discontinue or modify the dosage of the current biologic therapy, respectively. Globally, male patients (P = .001) with higher scholarity level (P = .005) displayed higher knowledge of COVID-19. Patients with lower DLQI (P = .006), longer disease duration (P = .051) and lower scholarity (P = .007) have thought to discontinue/modify autonomously their biologic therapy. At the multivariate logistic regression, only the knowledge of epidemiology and preventive measures resulted independent predictors of continuation vs discontinuation and modification vs no modification, respectively. Dermatologists should promote COVID-19 knowledge to prevent biologics disruption | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Multicenter Study | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a COVID-19 questionnaire | |
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a atopic dermatitis | |
650 | 4 | |a biologics | |
650 | 4 | |a hidradenitis suppurativa | |
650 | 4 | |a psoriasis | |
650 | 7 | |a Biological Products |2 NLM | |
700 | 1 | |a Riccò, Matteo |e verfasserin |4 aut | |
700 | 1 | |a Pacifico, Alessia |e verfasserin |4 aut | |
700 | 1 | |a Malagoli, Piergiorgio |e verfasserin |4 aut | |
700 | 1 | |a Kridin, Khalaf |e verfasserin |4 aut | |
700 | 1 | |a Pigatto, Paolo |e verfasserin |4 aut | |
700 | 1 | |a Damiani, Giovanni |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Dermatologic therapy |d 1998 |g 33(2020), 4 vom: 17. Juli, Seite e13508 |w (DE-627)NLM096394870 |x 1529-8019 |7 nnns |
773 | 1 | 8 | |g volume:33 |g year:2020 |g number:4 |g day:17 |g month:07 |g pages:e13508 |
856 | 4 | 0 | |u http://dx.doi.org/10.1111/dth.13508 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 33 |j 2020 |e 4 |b 17 |c 07 |h e13508 |